News

BioMarin Pharmaceutical (NASDAQ:BMRN) Beats Q1 Sales Targets

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 14.8% year on year to $745.1 million. The company expects the full year’s revenue to be around $3.15 billion, close to analysts’ estimates. Its non-GAAP profit of $1.13 per share was 18.6% above analysts’ consensus estimates.

Paylocity’s (NASDAQ:PCTY) Q1 Sales Beat Estimates, Provides Encouraging Quarterly Revenue Guidance

Payroll and human resources software provider, Paylocity (NASDAQ:PCTY) announced better-than-expected revenue in Q1 CY2025, with sales up 13.3% year on year to $454.5 million. Guidance for next quarter’s revenue was better than expected at $388 million at the midpoint, 1.5% above analysts’ estimates. Its non-GAAP profit of $2.43 per share was 14.8% above analysts’ consensus estimates.

Five9 (NASDAQ:FIVN) Exceeds Q1 Expectations

Call center software provider Five9 (NASDAQ: FIVN) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 13.2% year on year to $279.7 million. The company expects next quarter’s revenue to be around $275 million, close to analysts’ estimates. Its non-GAAP profit of $0.64 per share was 32.5% above analysts’ consensus estimates.

Roku (NASDAQ:ROKU) Surprises With Q1 Sales But Quarterly Revenue Guidance Significantly Misses Expectations

Streaming TV platform Roku (NASDAQ: ROKU) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 15.8% year on year to $1.02 billion. On the other hand, next quarter’s revenue guidance of $1.07 billion was less impressive, coming in 1.6% below analysts’ estimates. Its GAAP loss of $0.19 per share was 27.4% above analysts’ consensus estimates.